A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Michael Unterhalt, Michael Pfreundschuh et al.|Blood|2007Cited by 971
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Oliver Weigert, Vindi Jurinović et al.|The Lancet Oncology|2015Cited by 613
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Wolfgang Hiddemann, Martin Dreyling et al.|Journal of Clinical Oncology|2005Cited by 573
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Fowler, Catherine Thiéblemont, Michael Dickinson et al.|Nature Medicine|2021Cited by 523
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Wolfgang Hiddemann, Michael Unterhalt et al.|Blood|2006Cited by 465